Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis.
Journal
Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia
ISSN: 1806-3756
Titre abrégé: J Bras Pneumol
Pays: Brazil
ID NLM: 101222274
Informations de publication
Date de publication:
2022
2022
Historique:
received:
22
09
2021
accepted:
30
10
2021
entrez:
1
6
2022
pubmed:
2
6
2022
medline:
7
6
2022
Statut:
epublish
Résumé
Multidrug-resistant tuberculosis (MDR-TB) is a life-threatening infectious disease. Treatment requires multiple antimicrobial agents used for extended periods of time. The present study sought to evaluate the treatment success rate of bedaquiline-based regimens in MDR-TB patients. This was a systematic review and meta-analysis of studies published up to March 15, 2021. The pooled treatment success rates and 95% CIs were assessed with the fixed-effect model or the random-effects model. Values of p < 0.05 were considered significant for publication bias. A total of 2,679 articles were retrieved by database searching. Of those, 29 met the inclusion criteria. Of those, 25 were observational studies (including a total of 3,536 patients) and 4 were experimental studies (including a total of 440 patients). The pooled treatment success rate was 74.7% (95% CI, 69.8-79.0) in the observational studies and 86.1% (95% CI, 76.8-92.1; p = 0.00; I2 = 75%) in the experimental studies. There was no evidence of publication bias (p > 0.05). In patients with MDR-TB receiving bedaquiline, culture conversion and treatment success rates are high even in cases of extensive resistance.
Identifiants
pubmed: 35649043
pii: S1806-37132022000201200
doi: 10.36416/1806-3756/e20210384
pmc: PMC8836629
pii:
doi:
Substances chimiques
Antitubercular Agents
0
Diarylquinolines
0
bedaquiline
78846I289Y
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Research Support, Non-U.S. Gov't
Langues
eng
por
Sous-ensembles de citation
IM
Pagination
e20210384Références
Respir Med. 2020 Jun;167:105956
pubmed: 32421540
Biometrics. 1994 Dec;50(4):1088-101
pubmed: 7786990
Indian J Tuberc. 2020 Apr;67(2):222-230
pubmed: 32553316
Eur Respir J. 2018 Mar 22;51(3):
pubmed: 29545276
Eur Respir J. 2021 Jun 10;57(6):
pubmed: 33334942
Clin Infect Dis. 2020 Dec 3;71(9):2336-2344
pubmed: 31712809
Eur Respir J. 2018 Dec 20;52(6):
pubmed: 30361246
Eur Respir J. 2018 Jul 4;52(1):
pubmed: 29903862
Eur Respir J. 2011 Sep;38(3):516-28
pubmed: 21828024
Clin Infect Dis. 2019 Apr 24;68(9):1522-1529
pubmed: 30165431
Lancet Respir Med. 2019 Dec;7(12):1048-1058
pubmed: 31732485
Int J Infect Dis. 2020 Mar;92S:S15-S25
pubmed: 32032752
Eur Respir J. 2016 Feb;47(2):564-74
pubmed: 26647431
Eur Respir J. 2019 Dec 19;54(6):
pubmed: 31601711
Emerg Infect Dis. 2017 Oct;23(10):
pubmed: 28758889
Indian J Pharmacol. 2016 Mar-Apr;48(2):186-91
pubmed: 27127322
Front Microbiol. 2017 Apr 25;8:681
pubmed: 28487675
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
J Biol Chem. 2008 Sep 12;283(37):25273-25280
pubmed: 18625705
Indian J Tuberc. 2020 Jan;67(1):29-37
pubmed: 32192613
Eur Respir J. 2017 May 21;49(5):
pubmed: 28529205
Eur Respir J. 2021 Mar 4;57(3):
pubmed: 33093123
Clin Infect Dis. 2020 Aug 14;71(4):1010-1016
pubmed: 31556947
Antimicrob Agents Chemother. 2007 Nov;51(11):4202-4
pubmed: 17709466
Clin Microbiol Infect. 2021 Apr;27(4):597-602
pubmed: 32553880
Respir Investig. 2020 Jan;58(1):45-51
pubmed: 31635903
N Engl J Med. 2020 Mar 5;382(10):893-902
pubmed: 32130813
Int J Infect Dis. 2020 Sep;98:478-485
pubmed: 32640367
Science. 2005 Jan 14;307(5707):223-7
pubmed: 15591164
Pulmonology. 2021 Sep-Oct;27(5):403-412
pubmed: 33753021
Int J Tuberc Lung Dis. 2020 Dec 1;24(12):1265-1271
pubmed: 33317670
Emerg Infect Dis. 2019 May;25(5):936-943
pubmed: 31002070
PLoS One. 2020 Aug 4;15(8):e0236264
pubmed: 32750060
Eur Respir J. 2020 Jan 16;55(1):
pubmed: 31619478
N Engl J Med. 2014 Aug 21;371(8):723-32
pubmed: 25140958
Public Health Action. 2019 Sep 21;9(Suppl 1):S73-S79
pubmed: 31579654
Infect Dis Ther. 2021 Mar;10(1):457-470
pubmed: 33515206
Indian J Tuberc. 2019 Jan;66(1):184-188
pubmed: 30878066
Eur Respir J. 2017 Mar 22;49(3):
pubmed: 28182570
Lancet Infect Dis. 2018 May;18(5):536-544
pubmed: 29452942
Eur Respir J. 2021 Apr 8;57(4):
pubmed: 33833074
Int J Tuberc Lung Dis. 2018 Jul 1;22(7):766-772
pubmed: 29914602